Commentary: oral or enteral nutritional supplementation in cirrhosis – authors’ reply
Article first published online: 17 APR 2013
© 2013 Blackwell Publishing Ltd
Alimentary Pharmacology & Therapeutics
Volume 37, Issue 10, page 1023, May 2013
How to Cite
Ney, M., Vandermeer, B., Ma, M. M., Gramlich, L. and Tandon, P. (2013), Commentary: oral or enteral nutritional supplementation in cirrhosis – authors’ reply. Alimentary Pharmacology & Therapeutics, 37: 1023. doi: 10.1111/apt.12309
- Issue published online: 17 APR 2013
- Article first published online: 17 APR 2013
- Manuscript Accepted: 21 MAR 2013
- Manuscript Received: 20 MAR 2013
We thank Dr Cardenas for his comments about our recent meta-analysis.[1, 2] We agree with his conclusions and fully support the fundamental role that nutritional assessment and nutritional supplementation play in patients with cirrhosis.
The trial by Cabre et al. is an important one, and as Dr Cardenas points out, the nutritional intervention was associated with significant benefits. This trial was excluded from our meta-analysis, however, as these patients received branched chain amino acid (BCAA) supplementation. The role of BCAA-specific supplementation still requires further study. Due to the potentially unique pathophysiological properties of these agents and the fact that they are not available for routine use, we elected to exclude such BCAA trials from our review.
The authors’ declarations of personal and financial interests are unchanged from those in the original article.2
- 1Commentary: oral or enteral nutritional supplementation in cirrhosis. Aliment Pharmacol Ther 2013; 37: 1022–3..